Symptomatic Neurogenic Orthostatic Hypotension

• CLINICAL_TRIALS withdrawal · 2023-01-20
  Clinical Trial Update: Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]

  Phase 3 trial of TD-9855 for symptomatic neurogenic orthostatic hypotension was terminated; results were posted in 2023.

• CLINICAL_TRIALS trial_result · 2022-11-30
  Clinical Trial Update: Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]

  Phase 3 open-label extension studying TD-9855 for symptomatic neurogenic orthostatic hypotension due to primary autonomic failure was termin…

• CLINICAL_TRIALS trial_result · 2013-03-20
  Clinical Trial Update: Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa [Phase 1]

  A Phase 1 study assessed the pharmacokinetics and fed-versus-fasted bioequivalence of 300 mg droxidopa capsules in symptomatic neurogenic or…